



## Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

November 19, 2020

SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:



- Matt Abernethy, Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will present at the Piper Sandler 32<sup>nd</sup> Annual Virtual Healthcare Conference at 10:00 a.m. Eastern Time on Monday, November 23, 2020.
- Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Evercore ISI 3<sup>rd</sup> Annual HealthCONx Conference at 1:50 p.m. Eastern Time on Tuesday, December 1, 2020.

The live presentations will be webcast and may be accessed on the Company's website under Investors at [www.neurocrine.com](http://www.neurocrine.com). A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

### About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis\*, uterine fibroids\* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit [neurocrine.com](http://neurocrine.com), and follow the company on [LinkedIn](#). (\*in collaboration with AbbVie)

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301177243.html>

SOURCE Neurocrine Biosciences, Inc.

Navjot Rai (Media), 858-617-7623, [media@neurocrine.com](mailto:media@neurocrine.com), Todd Tushla (Investors), 858-617-7143, [ir@neurocrine.com](mailto:ir@neurocrine.com)